Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center.

Ann-Lorie GagnonWilliam BeauchesneLaurence TessierCharles DavidDjamal BerbicheAlexandre LavoieAlban Michaud-HerbstKarine Tremblay

Published in: Crohn's & colitis 360 (2021)

This study presents long-term treatment persistence data with adalimumab, infliximab, and vedolizumab, showing that more than half of cases treated with these biologics remained on treatment at least 24 months after initiation.

Keyphrases

ulcerative colitis
rheumatoid arthritis
primary care
combination therapy
electronic health record
deep learning